期刊
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 148, 期 3, 页码 889-894出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2021.02.023
关键词
Mastocytosis; anaphylaxis; tryptase; mast cell; plasma proteomic; PAPP-A; galectin-3; allergin-1; TPSAB1
资金
- Swedish Research Council - Medicine and Health
- Swedish Cancer Society
- Swedish Heart-Lung Foundation
- Ellen, Walter and Lennart Hesselman's Foundation
- Konsul ThC Berghs Foundation
- Stockholm County Council Research Funds (ALF)
- ChAMP (Centre for Allergy Research Highlights Asthma Markers of Phenotype) consortium - Swedish Foundation for Strategic Research
- AstraZeneca
- Karolinska Institutet
- Science for Life Laboratory Joint Research Collaboration
This study identified a group of potential biomarkers in plasma that could be used to predict patients with mastocytosis at increased risk of anaphylaxis. In addition to known markers, four novel proteins were discovered, providing important value in screening and identifying patients with this condition.
Background: Mastocytosis encompasses a heterogeneous group of disorders characterized by accumulation of clonal mast cells (MCs) in the skin and/or internal organs. Patients typically present with a broad variety of recurrent mediator-related clinical symptoms, including severe anaphylaxis. However, not all patients with mastocytosis experience anaphylactic reactions. Objective: We sought to identify disease-specific biomarkers in plasma that could be used to predict patients with mastocytosis with increased risk of anaphylaxis. Methods: Nineteen patients (>_18 years) and 2 control groups (11 subjects with allergic asthma and 13 healthy volunteers without history of atopy) were recruited. In total, 248 plasma proteins were analyzed by Proximity Extension Assay using Olink Proseek Multiplex panels. Results: We identified 4 novel proteins, in addition to tryptase, E-selectin, adrenomedullin, T-cell immunoglobulin, and mucin domain 1, and CUB domain-containing protein 1/CD138 to be significantly increased in patients with mastocytosis compared with both patients with asthma and healthy controls. Furthermore, we investigated whether we could discriminate between patients with mastocytosis with or without anaphylaxis. In addition to tryptase, we identified 3 novel proteins, that is, allergin-1, pregnancy-associated plasma protein-A, and galectin-3, with significantly different levels in patients with mastocytosis with anaphylaxis compared with those without anaphylaxis. Conclusions: Newly identified proteomic biomarkers may be used to predict patients with mastocytosis with increased risk of anaphylaxis. (J Allergy Clin Immunol 2021;148:889-94.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据